Nuclear medicine in South Korea began in 1959 with the measurement of 131I uptake and excretion in patients with thyroid diseases and has achieved remarkable progress over the past 60 years. Diagnostic nuclear medicine imaging in South Korea, introduced in 1961, has evolved to include gamma camera imaging using gamma cameras and positron emission tomography (PET) combined with computed tomography (CT), which are now established as primary diagnostic modalities. The radionuclides used in gamma cameras and PET/CT are produced by generators and cyclotrons. These radionuclides are labeled to compounds that are selectively taken up by target organs, thereby forming radiopharmaceuticals. In South Korea, some of the commonly used radiopharmaceuticals for diagnostic nuclear medicine imaging in patients with pancreaticobiliary diseases include 99mTc-dicarboxypropane diphosphonate (DPD), 99mTc-methylene diphosphonate (MDP), 99mTc-hydroxymethylene diphosphonate (HMDP), 99mTc-bromotriethyl-iminodiacetic acid (BrIDA or mebrofenin), 18F-fluorodeoxyglucose (18F-FDG), 18F-2-fluoro-3,4-dihydroxyphenylalanine (18F-FDOPA), 111In-pentetreotide (octreotide), and 68Ga-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid0-Tyr3-octreotide (68Ga-DOTA-TOC), which are widely used for the diagnosis and therapeutic planning of pancreaticobiliary neoplasms. The medical radiation exposure associated with diagnostic nuclear medicine imaging is considered to be at an acceptable level compared to radiation doses from natural background radiation. When clinicians understand the characteristics and advantages of nuclear medicine diagnostic imaging and effectively communicate this information to patients, this can contribute to building trust and improving the quality of medical care.

Nuclear medicine in South Korea began in 1959 with the measurement of 131I uptake and excretion in patients with thyroid diseases and has achieved remarkable progress over the past 60 years. Diagnostic nuclear medicine imaging in South Korea, introduced in 1961, has evolved to include gamma camera imaging using gamma cameras and positron emission tomography (PET) combined with computed tomography (CT), which are now established as primary diagnostic modalities. The radionuclides used in gamma cameras and PET/CT are produced by generators and cyclotrons. These radionuclides are labeled to compounds that are selectively taken up by target organs, thereby forming radiopharmaceuticals. In South Korea, some of the commonly used radiopharmaceuticals for diagnostic nuclear medicine imaging in patients with pancreaticobiliary diseases include 99mTc-dicarboxypropane diphosphonate (DPD), 99mTc-methylene diphosphonate (MDP), 99mTc-hydroxymethylene diphosphonate (HMDP), 99mTc-bromotriethyl-iminodiacetic acid (BrIDA or mebrofenin), 18F-fluorodeoxyglucose (18F-FDG), 18F-2-fluoro-3,4-dihydroxyphenylalanine (18F-FDOPA), 111In-pentetreotide (octreotide), and 68Ga-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid0-Tyr3-octreotide (68Ga-DOTA-TOC), which are widely used for the diagnosis and therapeutic planning of pancreaticobiliary neoplasms. The medical radiation exposure associated with diagnostic nuclear medicine imaging is considered to be at an acceptable level compared to radiation doses from natural background radiation. When clinicians understand the characteristics and advantages of nuclear medicine diagnostic imaging and effectively communicate this information to patients, this can contribute to building trust and improving the quality of medical care.

Nuclear medicine in South Korea began in 1959 with the measurement of 131I uptake and excretion in patients with thyroid diseases and has achieved remarkable progress over the past 60 years. Diagnostic nuclear medicine imaging in South Korea, introduced in 1961, has evolved to include gamma camera imaging using gamma cameras and positron emission tomography (PET) combined with computed tomography (CT), which are now established as primary diagnostic modalities. The radionuclides used in gamma cameras and PET/CT are produced by generators and cyclotrons. These radionuclides are labeled to compounds that are selectively taken up by target organs, thereby forming radiopharmaceuticals. In South Korea, some of the commonly used radiopharmaceuticals for diagnostic nuclear medicine imaging in patients with pancreaticobiliary diseases include 99mTc-dicarboxypropane diphosphonate (DPD), 99mTc-methylene diphosphonate (MDP), 99mTc-hydroxymethylene diphosphonate (HMDP), 99mTc-bromotriethyl-iminodiacetic acid (BrIDA or mebrofenin), 18F-fluorodeoxyglucose (18F-FDG), 18F-2-fluoro-3,4-dihydroxyphenylalanine (18F-FDOPA), 111In-pentetreotide (octreotide), and 68Ga-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid0-Tyr3-octreotide (68Ga-DOTA-TOC), which are widely used for the diagnosis and therapeutic planning of pancreaticobiliary neoplasms. The medical radiation exposure associated with diagnostic nuclear medicine imaging is considered to be at an acceptable level compared to radiation doses from natural background radiation. When clinicians understand the characteristics and advantages of nuclear medicine diagnostic imaging and effectively communicate this information to patients, this can contribute to building trust and improving the quality of medical care.

Nuclear medicine in South Korea began in 1959 with the measurement of 131I uptake and excretion in patients with thyroid diseases and has achieved remarkable progress over the past 60 years. Diagnostic nuclear medicine imaging in South Korea, introduced in 1961, has evolved to include gamma camera imaging using gamma cameras and positron emission tomography (PET) combined with computed tomography (CT), which are now established as primary diagnostic modalities. The radionuclides used in gamma cameras and PET/CT are produced by generators and cyclotrons. These radionuclides are labeled to compounds that are selectively taken up by target organs, thereby forming radiopharmaceuticals. In South Korea, some of the commonly used radiopharmaceuticals for diagnostic nuclear medicine imaging in patients with pancreaticobiliary diseases include 99mTc-dicarboxypropane diphosphonate (DPD), 99mTc-methylene diphosphonate (MDP), 99mTc-hydroxymethylene diphosphonate (HMDP), 99mTc-bromotriethyl-iminodiacetic acid (BrIDA or mebrofenin), 18F-fluorodeoxyglucose (18F-FDG), 18F-2-fluoro-3,4-dihydroxyphenylalanine (18F-FDOPA), 111In-pentetreotide (octreotide), and 68Ga-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid0-Tyr3-octreotide (68Ga-DOTA-TOC), which are widely used for the diagnosis and therapeutic planning of pancreaticobiliary neoplasms. The medical radiation exposure associated with diagnostic nuclear medicine imaging is considered to be at an acceptable level compared to radiation doses from natural background radiation. When clinicians understand the characteristics and advantages of nuclear medicine diagnostic imaging and effectively communicate this information to patients, this can contribute to building trust and improving the quality of medical care.

Nuclear medicine in South Korea began in 1959 with the measurement of 131I uptake and excretion in patients with thyroid diseases and has achieved remarkable progress over the past 60 years. Diagnostic nuclear medicine imaging in South Korea, introduced in 1961, has evolved to include gamma camera imaging using gamma cameras and positron emission tomography (PET) combined with computed tomography (CT), which are now established as primary diagnostic modalities. The radionuclides used in gamma cameras and PET/CT are produced by generators and cyclotrons. These radionuclides are labeled to compounds that are selectively taken up by target organs, thereby forming radiopharmaceuticals. In South Korea, some of the commonly used radiopharmaceuticals for diagnostic nuclear medicine imaging in patients with pancreaticobiliary diseases include 99mTc-dicarboxypropane diphosphonate (DPD), 99mTc-methylene diphosphonate (MDP), 99mTc-hydroxymethylene diphosphonate (HMDP), 99mTc-bromotriethyl-iminodiacetic acid (BrIDA or mebrofenin), 18F-fluorodeoxyglucose (18F-FDG), 18F-2-fluoro-3,4-dihydroxyphenylalanine (18F-FDOPA), 111In-pentetreotide (octreotide), and 68Ga-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid0-Tyr3-octreotide (68Ga-DOTA-TOC), which are widely used for the diagnosis and therapeutic planning of pancreaticobiliary neoplasms. The medical radiation exposure associated with diagnostic nuclear medicine imaging is considered to be at an acceptable level compared to radiation doses from natural background radiation. When clinicians understand the characteristics and advantages of nuclear medicine diagnostic imaging and effectively communicate this information to patients, this can contribute to building trust and improving the quality of medical care.

A wave of new technologies has created opportunities for the cost-effective generation of high-throughput profiles of biological systems, foreshadowing a "data-driven science" era. The large variety of data available from biological research is also a rich resource that can be used for innovative endeavors. However, we are facing considerable challenges in big data deposition, integration, and translation due to the complexity of biological data and its production at unprecedented exponential rates. To address these problems, in 2020, the Korean government officially announced a national strategy to collect and manage the biological data produced through national R&D fund allocations and provide the collected data to researchers. To this end, the Korea Bioinformation Center (KOBIC) developed a new biological data repository, the Korea BioData Station (K-BDS), for sharing data from individual researchers and research programs to create a data-driven biological study environment. The K-BDS is dedicated to providing free open access to a suite of featured data resources in support of worldwide activities in both academia and industry.

Lespedeza cuneata (LC) is a perennial plant used in herbal medicine to treat numerous diseases, including prostatic hyperplasia, diabetes, early atherosclerosis, and hematuria. Reference collections of bioactive compounds of LC are crucial for the determination of their pharmacological properties. However, little is known regarding its anti-oxidative and anti-inflammatory effects in alveolar macrophage (MH-S) cells. This study examined whether LC can inhibit reactive oxygen species and Coal fly ash (CFA) induced inflammation in MH-S cells. The anti-oxidative effects of LC were evaluated using 1,1-diphenyl-2-picrylhydrazyl (DPPH) and 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) assays, anti-inflammatory effects were examined using nitric oxide (NO) assay, and cytotoxicity was analyzed using methyl thiazolyl tetrazolium assay. The expression of inflammatory cytokine genes was assessed through a reverse-transcription polymerase chain reaction. Our results revealed that LC exhibited high radical scavenging activity and a dose-dependent (7.8–1,000 μg/mL) inhibition of oxidation as compared to ascorbic acid and Trolox. It also inhibited CFA-induced NO production in MH-S cells. Moreover, it suppressed the CFA exposure-mediated expression of pro-inflammatory mediators and cytokines, including inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), interleukin (IL)-1β, IL-6, and tumor necrosis factor-α. These results suggest that LC is a potent antioxidant and anti-inflammatory agent that can be useful as a nutraceutical product.

BACKGROUND: Self-monitoring of blood glucose is an important component of therapy for diabetes mellitus. The aim of this study was to evaluate the analytic performance evaluation of blood monitoring system G400 according to ISO 15197:2013. METHODS: We evaluated the G400 according to the ISO 15197:2013 guideline, we measured precision, accuracy, interference of hematocrit and interfering substances, user performance. RESULTS: Repeatability and intermediate precision of G400 showed standard deviation 2.7–3.8 mg/dL, 2.4–3.6 mg/dL and coefficient of variation 1.9-2.9% and 1.7–3.7%, respectively. Accuracy measured 98–98.5%, satisfied acceptable criteria. Error grid analysis showed that all results of this study were in zone A. Hematocrit between 20% to 60% did not cause interference. Three of 24 interfering substances were not acceptable criteria, and dose-response evaluation was needed. CONCLUSIONS: This study showed that G400 was considered reliable results satisfying the ISO 15197:2013 criteria
Blood Glucose ; Blood Glucose Self-Monitoring ; Diabetes Mellitus ; Hematocrit

Juvenile xanthogranuloma is a benign cutaneous histiocytic proliferative disorder. It usually develops on the head and the trunk, but rarely develops in the digits. To date, only two cases of subungual juvenile xanthogranuloma have been reported in the literature. We present 2 young patients who had subungual juvenile xanthogranuloma.
Head ; Humans ; Xanthogranuloma, Juvenile